Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V. reported second-quarter 2026 results showing continued investment in its hereditary and acquired angioedema franchise built around oral bradykinin B2 receptor antagonist deucrictibant. The company remains pre-revenue and recorded a Q2 2026 net loss of €47.8 million, or €0.70 per share, compared with a €45.5 million loss a year earlier, driven by higher research and development and commercial build-out costs.
Q2 research and development expenses rose to €35.0 million, mainly from expanded Phase 3 activities (CHAPTER-3, open-label XR extensions, and CREAATE) and regulatory and medical affairs work ahead of potential launch of the immediate-release (IR) capsule. General and administrative expenses increased to €15.8 million, reflecting larger commercial and IT teams and pre-launch activities. For the first six months of 2026, the net loss was €87.0 million.
The U.S. FDA accepted the New Drug Application for deucrictibant IR for on-demand treatment of hereditary angioedema attacks with a PDUFA date of April 23, 2027, and the EMA validated the corresponding MAA. Topline data from CHAPTER-3, a pivotal Phase 3 prophylaxis study of the extended-release (XR) tablet, are expected in the third quarter of 2026. After a May 2026 equity offering, cash and cash equivalents were €318.3 million as of June 30, 2026, which management states extends the cash runway into 2028.
LSP V Cooperatieve U.A. and LSP V Management B.V. report their beneficial ownership of Pharvaris N.V. ordinary shares in this amended Schedule 13G as of June 30, 2026. LSP V is the record holder of 3,424,609 ordinary shares, each with a par value of Euro 0.12.
The filing states that these holdings represent 4.9% of Pharvaris’ ordinary shares, based on 69,666,453 shares outstanding following an underwritten offering that closed on May 11, 2026. The reporting persons have shared power to vote and dispose of 3,424,609 shares and no sole voting or dispositive power.
LSP V Management B.V. is the sole director of LSP V, and its managing directors Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to beneficially own the shares held by LSP V, although each of these individuals disclaims beneficial ownership. The filing also notes that the position is now 5 percent or less of the class.
On July 13, 2026, Pharvaris N.V. Chief Executive Officer Berndt Modig executed an open-market sale of 2,292 shares of common stock at a weighted average price of $34.9714, pursuant to a scheduled Rule 10b5-1 trading plan. Following this sale, he holds 132,917 shares directly and 950,000 shares indirectly through Schoodic Management BV.
Pharvaris N.V. Chief Medical Officer Lu Peng reported two tax-withholding dispositions tied to vesting of restricted stock units. The issuer withheld 117 and 109 common shares, totaling 226 shares, at $35.07 per share to cover tax obligations, leaving Peng with 65,405 shares held directly.
PHVS shareholder Berndt B.A.E. Modig has filed to sell up to 2,292 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an indicated aggregate value of $80,380.44 for a planned trade date of July 13, 2026. The shares relate to Restricted Stock Units dated July 11, 2026 and the filing also lists prior Rule 10b5-1 sales in April, May, and June 2026 of about 2,291–2,292 shares each, with aggregate values between $65,558.53 and $71,172.89.
Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan reported open-market sales of company common stock under a pre-arranged Rule 10b5-1 trading plan. He sold 6,888 shares on June 29, 2026 at a weighted average price of $35.0533 per share and 30,712 shares on June 30, 2026 at a weighted average price of $35.4926 per share.
Following these transactions, he directly holds 315,167 Pharvaris common shares. Footnotes state that both sales were executed through multiple trades within daily price ranges of $35.00–$35.10 and $35.00–$35.90, respectively, and were carried out pursuant to his Rule 10b5-1 trading plan.
Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a mix of stock option exercises and share sales in Pharvaris common stock. She exercised options to acquire 37,572 shares at strike prices of $8.05 and $2.59 per share, then sold 76,172 shares in open-market transactions at weighted average prices around $35 per share. The filing states these were scheduled transactions under a Rule 10b5-1 trading plan and involved cashless exercise of options. After the transactions, she holds 58,750 shares directly and 93,969 shares indirectly through GrayMatters Consulting B.V., an entity she controls.
PHVS reports insider sales under pre-arranged 10b5-1 plans by Anne Simonne J. Lesage and Graymatters Consulting B.V. The excerpt lists multiple completed 10b5-1 sales of Common stock on specific dates in 2026, including 21,700 shares on 04/30/2026 and 8,300 shares on 06/29/2026 by the named parties.
The filing records each sale with the trade date and gross proceeds shown in dollars; cash-flow treatment and aggregate registered offering details are not included in the provided excerpt.
PHVS notice of proposed sales under Rule 144 and 10b5-1 plans by insiders and affiliated holders. The excerpt lists multiple 10b5-1 sales and an exercise of stock options that generated sales on and around 04/22/2026 through 06/30/2026. Named sellers include Anne Simonne J. Lesage and Graymatters Consulting B.V. with individual trade lines such as 21,700 shares on 04/30/2026 and 8,300 shares on 06/29/2026. The transactions are reported as brokered sales with cash consideration.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice relating to proposed sales of Common shares linked to Founders Shares. The filing also lists recent 10b5-1 sales by Hans H. Schikan, including 6,888 shares on 06/29/2026 for $241,447.13 and 29,070 shares on 04/30/2026 for $881,378.75.